Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35486
Title: Delayed Skin Testing for Systemic Medications: Helpful or Not?
Austin Authors: Barbaud, Annick;Goncalo, Margarida;Mockenhaupt, Maja;Copaescu, Ana ;Phillips, Elizabeth J
Affiliation: Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France.
Department of Dermatology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Dokumentationszentriúm schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center and Medical Faculty, University of Freiburg, Freiburg, Germany.
The Research Institute of McGill University Health Center, McGill University, Montreal, Canada.
Center for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.
Centre for Antibiotic Allergy and Research
Infectious Diseases
Issue Date: Sep-2024
Date: 2024
Publication information: The journal of Allergy and Clinical Immunology. In Practice 2024-09; 12(9)
Abstract: Cutaneous adverse drug reactions collectively are delayed drug reactions such as morbilliform drug eruption and severe cutaneous adverse reactions (SCARs). Morbilliform drug eruption may wane over time, be the result of drug viral interactions, and be amenable to slow reintroduction or rechallenge, whereas SCARs are HLA class I restricted, T-cell-mediated reactions that demonstrate durable immunity and warrant lifelong avoidance. SCARs such as drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome and toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption often occur in the setting of multiple drugs dosed together. Collectively, they lead to significant morbidity, mortality, and drug safety concerns that could severely limit future treatment options. Currently, no single or combination of diagnostic tests for SCARs such as ex vivo or in vitro testing, in vivo (skin) testing, or other adjunctive tests such as HLA typing have 100% negative predictive value. In this "Controversies in Allergy Review" article, we review the current literature on delayed skin testing (patch and delayed prick/intradermal test) and critically assess the evidence base of its utility across different drugs and clinical phenotypes of delayed hypersensitivity reactions.
URI: https://ahro.austin.org.au/austinjspui/handle/1/35486
DOI: 10.1016/j.jaip.2024.06.047
ORCID: 
Journal: The journal of Allergy and Clinical Immunology. In Practice
Start page: 2268
End page: 2277
PubMed URL: 38977212
ISSN: 2213-2201
Type: Journal Article
Subjects: DRESS
Drug patch tests
Intradermal tests
Maculopapular exanthema
Prick tests
Drug Eruptions/diagnosis
Drug Eruptions/immunology
Drug Hypersensitivity/diagnosis
Hypersensitivity, Delayed/diagnosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

38
checked on Nov 6, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.